Repare Therapeutics Statistics
Total Valuation
RPTX has a market cap or net worth of $76.04 million. The enterprise value is -$32.79 million.
Important Dates
The next estimated earnings date is Friday, November 7, 2025, before market open.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RPTX has 42.96 million shares outstanding. The number of shares has increased by 0.92% in one year.
| Current Share Class | 42.96M |
| Shares Outstanding | 42.96M |
| Shares Change (YoY) | +0.92% |
| Shares Change (QoQ) | +0.78% |
| Owned by Insiders (%) | 1.16% |
| Owned by Institutions (%) | 28.09% |
| Float | 22.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 304.15 |
| Forward PS | 7.45 |
| PB Ratio | 0.69 |
| P/TBV Ratio | 0.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.30, with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.30 |
| Quick Ratio | 6.18 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -69.96% and return on invested capital (ROIC) is -44.82%.
| Return on Equity (ROE) | -69.96% |
| Return on Assets (ROA) | -38.82% |
| Return on Invested Capital (ROIC) | -44.82% |
| Return on Capital Employed (ROCE) | -102.91% |
| Revenue Per Employee | $1,938 |
| Profits Per Employee | -$851,659 |
| Employee Count | 129 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, RPTX has paid $1.10 million in taxes.
| Income Tax | 1.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.97% in the last 52 weeks. The beta is 1.07, so RPTX's price volatility has been similar to the market average.
| Beta (5Y) | 1.07 |
| 52-Week Price Change | -50.97% |
| 50-Day Moving Average | 1.76 |
| 200-Day Moving Average | 1.43 |
| Relative Strength Index (RSI) | 43.33 |
| Average Volume (20 Days) | 201,961 |
Short Selling Information
The latest short interest is 620,829, so 1.45% of the outstanding shares have been sold short.
| Short Interest | 620,829 |
| Short Previous Month | 610,001 |
| Short % of Shares Out | 1.45% |
| Short % of Float | 2.73% |
| Short Ratio (days to cover) | 5.15 |
Income Statement
In the last 12 months, RPTX had revenue of $250,000 and -$109.86 million in losses. Loss per share was -$2.58.
| Revenue | 250,000 |
| Gross Profit | 15.36M |
| Operating Income | -113.63M |
| Pretax Income | -108.76M |
| Net Income | -109.86M |
| EBITDA | -110.47M |
| EBIT | -113.63M |
| Loss Per Share | -$2.58 |
Full Income StatementBalance Sheet
The company has $109.47 million in cash and $649,000 in debt, giving a net cash position of $108.82 million or $2.53 per share.
| Cash & Cash Equivalents | 109.47M |
| Total Debt | 649,000 |
| Net Cash | 108.82M |
| Net Cash Per Share | $2.53 |
| Equity (Book Value) | 110.41M |
| Book Value Per Share | 2.57 |
| Working Capital | 106.49M |
Full Balance SheetCash Flow
| Operating Cash Flow | -103.34M |
| Capital Expenditures | n/a |
| Free Cash Flow | -103.34M |
| FCF Per Share | -$2.41 |
Full Cash Flow StatementMargins
| Gross Margin | 6,145.60% |
| Operating Margin | -45,450.00% |
| Pretax Margin | -43,504.40% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RPTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.92% |
| Shareholder Yield | -0.92% |
| Earnings Yield | -144.49% |
| FCF Yield | -135.90% |
Analyst Forecast
The average price target for RPTX is $3.50, which is 97.74% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.50 |
| Price Target Difference | 97.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RPTX has an Altman Z-Score of -4.06 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.06 |
| Piotroski F-Score | 2 |
